Billiontoone (NASDAQ:BLLN) CEO Sells 26,250 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) CEO Oguzhan Atay sold 26,250 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $122.05, for a total transaction of $3,203,812.50. Following the transaction, the chief executive officer directly owned 20,000 shares in the company, valued at approximately $2,441,000. This represents a 56.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Monday, July 6th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total transaction of $1,525,625.00.
• On Monday, June 8th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $1,227,750.00.
• On Monday, June 8th, Oguzhan Atay sold 26,250 shares of Billiontoone stock. The shares were sold at an average price of $97.66, for a total transaction of $2,563,575.00.

Billiontoone Trading Up 2.2%

Shares of NASDAQ:BLLN traded up $2.56 on Wednesday, reaching $120.60. 630,319 shares of the company traded hands, compared to its average volume of 700,015. The business’s 50-day simple moving average is $98.44 and its 200 day simple moving average is $88.44. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. The company’s revenue was up 83.8% on a year-over-year basis. During the same period last year, the firm posted ($0.39) EPS. Analysts expect that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on BLLN shares. BTIG Research dropped their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Guggenheim began coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $126.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BLLN. Rossby Financial LCC bought a new position in Billiontoone during the 4th quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC purchased a new position in shares of Billiontoone during the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Billiontoone during the fourth quarter valued at approximately $82,000. Finally, Thrive Wealth Management LLC bought a new position in shares of Billiontoone during the second quarter valued at approximately $240,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.